MarginsXMarginsX
Home › Markets › Health Care › DNTH

Dianthus Therapeutics Inc. (DNTH)

DNTH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$89.55
-2.46% on the day
Market cap
$5.0B
Mid cap
Revenue · 2025
$2.0M
-67.3% on 2024
Net income · 2025
-$162.3M
-7973.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/0001690585-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDNTH on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001690585
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.0M
Net income-$162.3M
Operating income-$177.9M
Net margin-7973.3%
Operating margin-8739.3%
Revenue growth-67.3%
Cash$51.1M
Total assets$530.9M
P/E (computed)Net income was not positive
P/S (computed)2476.8×

Warning signs

Cash runway
3.8 months
$55.7M cash at September 30, 2026
Share count, 1 year
+31.3%
2025-11-03 to 2026-11-02 · +280.0% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$71.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying u"
10-Q 2026-11-04
Cash and burn$55.7M cash; operating cash flow -$43.8M a quarter.Report 2026-09-30
Shares outstanding56,312,712 (2026-11-02); 42,876,015 a year earlier; 14,817,762 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-03-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Morristown, New Jersey, United StatesPCAOB Form AP 2026-03-14
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $71.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$46.6M-$50.3M$55.7MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$50.2M-$49.0M$110.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$40.8M-$28.9M$627.7MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
$284K-$64.4M-$47.0M$51.1MNo debt tags$2.0M10-K 2026-03-09
Q3 2025
2025-09-30
$396K-$36.8M-$30.6M$56.0MNo debt tags$3.1M10-Q 2025-11-05
Q2 2025
2025-06-30
$193K-$31.6M-$23.9M$13.2MNo debt tags$4.9M10-Q 2025-08-07
Q1 2025
2025-03-31
$1.2M-$29.5M-$27.6M$10.1MNo debt tags$6.5M10-Q 2025-05-12
Q4 2024
2024-12-31
$1.3M-$28.4M-$27.4M$22.8MNo debt tags$6.2M10-K 2026-03-09

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-09-18
Latest annual report10-K2026-03-09
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-09

Source: SEC EDGAR submissions feed, 661 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.7%
1 month+18.3%
3 months-16.2%
Year to date+122.8%
1 year+158.6%
From 52-week high-20.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LQDALiquidia Corporation$56.37-1.81%$5.1B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
ERASErasca Inc.$15.11-3.51%$5.3B
EWTXEdgewise Therapeutics Inc.$43.68-4.90%$4.8B
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
MANEVeradermics Incorporated$128.05-1.24%$5.4B
IONSIonis Pharmaceuticals Inc.$28.01-3.61%$4.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier